pf-04971729 has been researched along with Liver-Diseases* in 1 studies
1 trial(s) available for pf-04971729 and Liver-Diseases
Article | Year |
---|---|
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Ertugliflozin, an oral, highly selective inhibitor of the sodium-glucose cotransporter 2, is approved in the United States and the European Union for the treatment of adults with type 2 diabetes mellitus. Hepatic impairment may affect, to varying degrees, the absorption, metabolism, and excretion of drugs and may be associated with a lower plasma protein binding compared with that in healthy individuals. This study was conducted to assess the effect of hepatic impairment on the pharmacokinetic (PK), safety, and tolerability profiles of ertugliflozin after administration of a single, 15-mg oral dose.. This was a Phase I, open-label, single-dose study in healthy individuals (n = 8) and those with moderate hepatic impairment (n = 8). Eligible participants were men or women aged 18 to 75years with a body mass index of 18.0 to 40.5 kg/m. The adjusted least squares geometric meanratios for total ertugliflozin AUC. Moderate hepatic impairment had no clinically relevant effect on the PK and safety profiles of ertugliflozin. The results of this study support a recommendation for no dose adjustment of ertugliflozin in patients with mild or moderate hepatic impairment. Ertugliflozin was well tolerated when administered tohealthy individuals and patients with moderate hepatic impairment. ClinicalTrials.gov identifier: NCT02115347. Topics: Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Female; Humans; Liver Diseases; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2018 |